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ranges of the diagnostic performance were calculated both 
assuming that equivocal findings were positive and assum-
ing that they were negative for bone metastases. For the NaF 
PET/CT cohort the number of patients with signs of lymph 
node metastases on low dose CT were also recorded, includ-
ing the impact of these findings on clinical management.
Results One-hundred-and-four patients underwent NaF 
PET/CT, whereas 122 patients underwent BS. Sensitivi-
ties of 97–100 and 84–95% and specificities of 98–100 
and 72–100% were found on a patient basis for detection 
of bone metastases with NaF PET/CT and BS, respectively. 
Equivocal findings warranted further diagnostic procedures 
in 2% of the patients in the NaF cohort and in 16% in the BS 
cohort. In addition NaF PET/CT demonstrated lymph node 
metastases in 50% of the included patients, of which 25% 
showed evidence of lymph node metastases only.
Conclusion Our data indicate better diagnostic perfor-
mance of NaF PET/CT compared to BS for detection of bone 
metastases in primary staging of prostate cancer patients. 
Less equivocal findings are encountered with NaF PET/CT. 
Moreover, NaF PET/CT has additional value over BS since 
lymph node metastases are encountered frequently.
Keywords Prostate cancer · 18F-sodiumfluoride PET/
CT · Bone scan · Staging
Introduction
Prostate cancer is a highly prevalent malignancy in west-
ern countries, especially in older men. Of all types of can-
cer in men, prostate cancer has the highest incidence, and 
its mortality is surpassed only by lung and colon cancer 
(European Cancer Observatory, http://eu-cancer.iarc.fr/). 
In aggressive forms of prostate cancer, haematogenous 
Abstract 
Introduction/Aim Correct staging of patients with prostate 
cancer is important for treatment planning and prognosis. 
Although bone scintigraphy with 99mTc-phosphonates (BS) 
is generally advised for staging by guidelines in high risk 
prostate cancer, this imaging technique is hampered by a 
high  rate of inconclusive results and moderate accuracy. 
Potentially better imaging techniques for detection of bone 
metastases such as 18F-sodiumfluoride PET/CT (NaF PET/
CT) are therefore being evaluated. In this observational 
cohort study we evaluate the performance and clinical 
impact of both BS and NaF PET/CT  in primary staging of 
patients with prostate cancer.
Methods The first of two cohorts consisted of patients 
who received a BS while the second included patients who 
received a NaF PET/CT for primary staging of prostate can-
cer. For both cohorts the number of positive, negative and 
equivocal findings, calculated diagnostic performance of the 
imaging modality in terms of sensitivity and specificity, as 
well as the impact on clinical management were studied. The 
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spread occurs primarily to the hematopoietic red marrow 
of the skeleton. The presence of such metastatic bone dis-
ease markedly influences prognosis, and early diagnosis of 
skeletal involvement is necessary for appropriate patient 
management [1].
Since the 1960s it is recognised that bone scintigraphy 
(BS) is capable of detecting bone metastases well before 
radiological change. Successful bone imaging was achieved 
in 1961 by Felming et al. [2] using 85Sr. Due to the large 
radiation burden and slow clearance of tracer from the blood 
pool this radioisotope was far from ideal. A few years later 
87mSr and 18F were introduced as alternatives for 85Sr [3, 4]. 
However, for 87mSr the slow tracer extraction from soft tis-
sues still prohibited sufficient image quality. 18F with its fast 
blood clearance and high skeletal uptake resulted in more 
satisfactory images. However the low availability of this 
isotope, which is cyclotron produced and has a relatively 
low half-life of 110 min, and the relatively high energy of 
the emitted photons of 18F (511 keV), which is not ideal for 
detection with an Anger gamma-camera, prevented its use in 
clinical routine. In 1971 the first radiopharmaceutical based 
on a phosphonate labelled with 99mTc became available [5]. 
For that time, 99mTc had ideal properties for clinical use. 
First, there was a good availability of this isotope, since it 
was used for other nuclear medicine procedures, which had 
become routine clinical practice and second, the relatively 
low photon energy (140 keV) with a half-life of 6 h was 
suitable for imaging with an Anger gamma-camera. Further 
developments resulted in introduction of 99mTc-methylene 
diphosphonate (99mTc-MDP) and 99mTc-hydroxymethylene 
diphosphonate (99mTC-HDP) which are the most commonly 
used tracers for bone imaging with a gamma-camera [6, 7].
For decades European and US guidelines recommend 
bone scintigraphy with 99mTc-phosphonates for bone metas-
tasis assessment, which, if necessary can be complemented 
by radiographic survey [8, 9]. A closer look at the present 
guidelines reveals that the guidelines are mainly based on 
30 years-old studies which found that BS was the most sensi-
tive diagnostic method at that time and on arguments involv-
ing the clinical impact of BS, for which the pre-test probabil-
ity for positive findings is used as a surrogate [10, 11]. The 
wide availability and technical improvements of Positron 
Emission Tomography/Computed Tomography (PET/CT) 
cameras after the introduction of 2-deoxy-2-(18F)fluoro-
d-glucose (18F-FDG) in standard medical imaging in the late 
1900s and early 2000s and the increasing insights in the 
diagnostic value of 99mTc-MDP and 99mTc-HDP bone scans, 
with a moderate sensitivity and poor specificity, resulted in 
renewed interest in 18F as a bone tracer in medical imaging. 
Although 18F-sodiumfluoride (NaF) PET/CT performed bet-
ter than 99mTc-HDP bone scan (BS) in comparative studies, 
data is still limited due to relatively small studied cohorts 
and the inclusion of mixed patient populations [12–15].
In January 2014 NaF PET/CT for detection of bone 
metastases was introduced in our clinical practice. Before 
this date BS was routinely performed. For all patients that 
received a NaF PET/CT on our department patient data was 
prospectively entered in a database for quality assessment 
and educational purposes. In this study we present the data 
of a cohort of patients that received NaF PET/CT and a 
cohort of patients that received BS for primary staging of 
prostate cancer. For both cohorts, the number of positive, 
negative and equivocal findings, found diagnostic perfor-
mance of the imaging modality, including sensitivity and 
specificity, and impact on clinical management are reported. 
For the NaF PET/CT cohort the number of patients with 
signs of lymph node metastases on low dose CT are also 
reported, including the impact of these findings on clinical 
management.
Materials and methods
Both cohorts included patients who received either BS or 
NaF PET/CT for initial staging of histopathologically or 
clinically proven prostate cancer. Clinically proven pros-
tate cancer was defined as elevated PSA > 20 ng/ml and 
a clear prostate tumour by digital exam. The retrospective 
BS cohort included all consecutive patients from January 
2011 till April 2012, while patients were included in the NaF 
PET/CT cohort from January 2014 till July 2016. Patients 
who had a second malignancy, except basal cell carcinoma 
of the skin, or for whom no follow-up data were available 
were excluded from the analysis. All patients gave written 
informed consent for the use of their anonymous data for 
scientific purposes. Besides the standard imaging protocol 
and standard clinical management no additional measure-
ments or actions affecting the patient were performed. The 
study passed the local scientific board and approval of the 
local ethical committee for the present study was waived 
since the study does not fall within the scope of the Dutch 
Medical Research Involving Human Subjects Act (Sect. 1.b 
WMO, 26th February 1998).
Bone scintigraphy consisted of planar images of the entire 
skeleton, which were acquired using a dual-headed camera, 
2–3 h after intravenous injection of a standard dosage of 
550 MBq (range 515–589) of 99mTc-HDP (General Elec-
tric Millenium™ VG3 or General Electric Millennium™ 
VG5 + hawkeye option). NaF PET/CT images were acquired 
60 min after intravenous administration (90 s per bed posi-
tion) of 2.5 MBq/kg body weight 18F-Sodiumfluoride (Mean 
189, range 146–271) on a Siemens Biograph-16 TruePoint 
PET/CT (Siemens Healthcare, Knoxville, USA). Recon-
struction was done by means of an iterative OSEM3D algo-
rithm using 4 iterations and 8 subsets and a 5 mm Gaussian 
filter. Reconstructed images had an image matrix size of 
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168 × 168, a pixel spacing of 4.07 × 4.07 mm and a slice 
thickness of 5 mm. For attenuation correction a low-dose 
CT was acquired using a tube current of 25 mAs at 110 kV, 
collimation 16 × 1.2 mm and a pitch of 0.95. CT images 
were reconstructed using a slice thickness of 5.0 mm and a 
matrix size of 512 × 512.
All images were separately re-interpreted by two nuclear 
medicine physicians (MW and FZ) who were blinded to 
other imaging, biochemical, or histopathological findings 
and to the clinical follow-up. For each patient, the BS or NaF 
PET/CT was scored as no metastases, equivocal or positive 
for metastases. Cases demonstrating focal and intense tracer 
uptake that could not be related to benign processes were 
scored as malignant. Cases with irregular tracer uptake in 
the spine in the absence of other signs of metastases, and 
those with focal tracer uptake due to degenerative verte-
bral joints, were scored as no metastases. Rib lesions were 
categorized as malignant when these presented elongated 
uptake or when multiple randomly ordered findings of focal 
costal uptake was encountered, as benign when these verti-
cally involved several ribs, and otherwise as equivocal. Low-
dose CT images of the NaF PET/CT were evaluated for the 
presence of lymph node metastases, defined as lymph nodes 
with a short axis of at least 1.0 cm in the para iliac region/
obturator fossa. In case of differences in image interpreta-
tion, decisive categorization was performed in consensus. 
According to a literature review on the role of BS in baseline 
staging of newly diagnosed prostate cancer by Abuzallouf 
et al. [16.] patients were categorised by PSA level (< 10, 
10.0–19.9, 20–49.9, 50–99.9 and > 100 ng/ml) and Gleason 
score (≤ 7, ≥ 8 and unknown).
The used composite reference standard (RS) comprised a 
follow-up period of at least 18 months for the BS cohort and 
at least 6 months for the NaF PET/CT cohort, and included 
staging imaging, follow-up imaging (BS, MRI, CT, X-ray, 
18F-fluorocholine-PET/CT, and/or 18F-FDG-PET/CT), bio-
chemical follow-up, and clinical follow-up.
The diagnostic performance of each modality, including 
sensitivity, specificity, positive predictive value (PPV), nega-
tive predictive value (NPV) and accuracy, were calculated 
by comparison of the BS and NaF PET/CT results with the 
RS. Because both cohorts contained scans with equivocal 
results the ranges of the diagnostic performance were cal-
culated both assuming that equivocal findings were positive 
and assuming that they were negative for bone metastases.
For all patients impact of BS and NaF PET/CT on clinical 
management was scored. For the retrospective BS cohort 
this was done by thorough survey of the electronic medical 
records. For the NaF PET/CT cohort this was scored during 
the urologic-oncologic multidisciplinary meeting. Changes 
in clinical management based on NaF PET/CT results were 
divided in changes based on findings of bone metastases and 
changes based on found extra-osseous metastases.
Results
The BS cohort and NaF PET/CT cohort included 136 and 
107 patients, respectively. Of these, respectively 14 and 3 
patients were excluded due to a presence of an additional 
primary malignancy. Respectively 106 and 95 patients had 
histopathologically proven prostate cancer and 16 and 9 had 
clinically proven prostate cancer. Histopathological prove 
of the disease in this group was waived in case of absence 
of treatment options with curative intent or when patients 
refused from those potential curative options. Patient’s char-
acteristics for both cohorts are presented in Table 1.
With BS and NaF PET/CT respectively, lesions char-
acteristic for bone metastases were found in 33/122 and 
61/104 patients (27 and 59%), no signs of metastases were 
found in 61/122 and 40/104 (50 and 39%) patients, and for 
28/122 and 3/104 (23 and 3%) results were equivocal. Fig-
ure 1 shows the findings for PSA categories < 10, 10–19.9, 
20–49.9, 50–99.9 and ≥ 100 ng/ml and Fig. 2 displays the 
findings for categories Gleason ≤ 7, ≥ 8 and unknown  Glea-
son score. Figures 3 and 4 show examples of BS and NaF 
PET/CT with equivocal results. For all patients with signs of 
bone metastases curative options were abandoned.
For two cases in the BS cohort no RS was available: 
one patient died 6 weeks after BS due to cardiovascular 
disease, and one patient went to another hospital for a 
second opinion. These were excluded from further analy-
sis. For the remaining 120 BSs and the 104 NaF PET/
CTs, the imaging findings were compared with the RS 
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and subsequently the diagnostic characteristics were calcu-
lated for both equivocal BSs and NaF PET/CTs considered 
positive and negative (Table 2). Found sensitivities ranged 
from 84.2 to 94.7% and from 96.8 to 100% for BS and NaF 
PET/CT and found specificities from 72.0 to 100 and 97.6 
to 100%, respectively. Overall accuracy of BS ranged from 
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Fig. 2  Findings on 99mTc-HDP bone scan and 18F-NaF PET/CT per Gleason-score category
Fig. 3  Anterior and posterior 
99mTc-HDP bone scan showing 
non-specific increased HDP 
uptake dorsally in the left 9th 
rib (red arrow). Subsequent 
X-thorax shows no signs of 
metastases. Patient received 
external radiation therapy with 
curative intent on the prostate 
in 2012. PSA levels decreased 
and PSA remained undetectable 
(< 0.1 ng/ml) until the latest 
measurement in August 2016
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According to the reference standard 5/28 (18%) equivo-
cal findings in the BS cohort were due to the presence of 
bone metastases, the other 23/28 (82%) equivocal findings 
were due to benign causes including degenerative disease. 
Equivocal findings resulted in additional imaging procedures 
in 19/28 patients (16% of the patients in the entire cohort) 
which included: MRI pelvis and total vertebral column in 10 
patients, CT abdomen and pelvis in 3 patients, MRI and CT 
in 1 patient, X-ray of the pelvis in 2 patients and chest X-ray 
(including detailed costal images) in 1 patient. In the NaF 
PET/CT cohort 2/3 (67%) of the equivocal findings were 
due to bone metastases. In 2 patients (2% of the patients 
in the entire cohort) additional imaging was used, consist-
ing of MRI of pelvis and vertebral column in both patients. 
No additional imaging was applied in the other patient who 
refused therapy with curative intent.
In the NaF PET/CT cohort low-dose CT images showed 
signs of lymph node metastases in 52/104 (50%) patients 
(Figs. 1c and 2c). Thirteen patients had signs of lymph node 
metastases only. According to the seventh TNM-classifica-
tion for prostate cancer only locoregional lymphadenopa-
thy (N1) was found in 7 of those patients. In one patient 
a histopathological biopsy of a lymph node near the right 
external iliac artery confirmed the presence of a lymph 
node metastasis of prostate cancer. For 5 patients, includ-
ing the patient with histopathologically proven lymph node 
metastasis, the multidisciplinary team advised radiation 
therapy with curative intent combined with 3 years andro-
gen deprivation therapy. For 2 patients palliative hormonal 
treatment was advised. One of those patients had a lymph 
node metastasis with a short axis of 7.0 cm and the other 
patient had severe co-morbidity. Locoregional as well as 
Fig. 4  18F-NaF PET, PET/
CT and CT images showing 
increased 18F- uptake in the 
right side of the os fronta-
lis without substrate on CT, 
unlikely for bone metastasis 
(red arrows). Increased 18F- 
uptake in the right 8th rib, with 
faint sclerosis on CT, equivocal 
for bone metastasis (yellow 
arrows). Increased 18F- uptake 
in degenerative changes in the 
lumbar spine and enthesopa-
thy in the trochanteric region 
at both sides (green arrows). 
83-years old patient abstained 
from therapy with curative 
intent and androgen deprivation 
therapy was initiated
Table 2  Diagnostic characteristics of BS and NaF-PET/CT
PPV positive predictive value, NPV negative predictive value
a Equivocal findings considered positive
b Equivocal findings considered negative




Sensitivity 94.7 84.2 100 96.8
Specificity 72.0 100 97.6 100
PPV 61.0 100 98.4 100
NPV 96.7 93.2 100 95.3
Accuracy 79.2 95.0 99.0 98.1
Equivocal prevalence 23.0 23.0 2.9 2.9
Disease prevalence 31.7 31.7 60.6 60.6
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non-regional lymphadenopathy without signs of bone metas-
tases (N1M1a) was found in 6 patients. No histopathologi-
cal biopsies were taken from suspected lymph nodes in this 
group. The multidisciplinary team advised palliative radia-
tion therapy for local disease control (two T4 tumours and 
one T3b) in combination with androgen deprivation therapy 
for 3 patients and only palliative androgen deprivation for 
the other 3 patients.
Discussion
As a consequence of the retrospective  nature of this study, 
differences between both cohorts in terms of patient char-
acteristics were observed (Table 1). The median PSA-value 
in the NaF cohort is higher compared to the BS cohort, and 
also Gleason score and T-stadium of the included patients 
in the NaF cohort are generally higher. As a result the prev-
alence of bone metastases in the NaF cohort is markedly 
higher than in the BS cohort (61 vs 32%). To overcome this 
problem the cohorts were subcategorised by PSA-value 
(Fig. 1) and Gleason-score (Fig. 2). In most PSA categories 
and all Gleason score categories NaF PET/CT detects bone 
metastases in a higher percentage of patients. This is also 
reflected by the higher sensitivity of NaF PET/CT (Table 2). 
Thereby for BS a trade-off between sensitivity and specific-
ity is found, while this trade-off is almost negligible for NaF 
PET/CT, which results in an overall high accuracy of NaF 
PET/CT compared to the moderate to high accuracy of BS. 
In all subcategories BS shows higher numbers of equivocal 
findings on a per patient basis compared to NaF PET/CT.
The presence or absence of metastasised disease at the 
time of initial diagnosis of prostate cancer has large con-
sequences on clinical management. According to most 
guidelines bone metastases preclude therapies with curative 
intent, however this perception is shifting. There is grow-
ing evidence that an intermediate oligometastatic state has 
favourable survival outcomes compared to patients with 
widespread metastatic disease. Some patients may be cur-
able with aggressive multimodality treatments [17]. For 
oligometastatic bone metastases stereotactic body radiation 
therapy has been shown to be safe and well tolerated with 
high local control rates [18–20]. In this perspective imag-
ing techniques with higher diagnostic performances, with 
both high sensitivity and high specificity become even more 
important for proper selection and evaluation of patients 
suited for these aggressive therapies.
Our findings are generally in line with previous studies, 
which have shown a high sensitivity and specificity for NaF 
PET/CT and in comparative studies NaF PET/CT performed 
better than BS. However literature remains scarce and most 
studies included both patients for staging and restaging of 
prostate cancer and included a smaller number of patients 
as compared to the cohorts in present study.
In a prospective study from 42 patients with prostate can-
cer, Langsteger et al. found a high diagnostic performance 
of NaF PET/CT with a sensitivity and specificity of 91 and 
83%, respectively [14]. In 24 prostate cancer patients Even-
Sapir and co-workers found a patient based sensitivity and 
specificity of 70 and 57%, respectively, for planar bone scin-
tigraphy compared to 100% sensitivity and specificity for 
NaF PET/CT [13]. In this study NaF PET/CT was also com-
pared to 99mTc-MDP SPECT, which reached a sensitivity of 
92% and a specificity of 82%. Found differences in sensitiv-
ity and specificity between BS or SPECT and NaF PET/CT 
were significant (P < 0.05). In 49 prostate cancer patients 
Damle et al. found a sensitivity of 100 and 96.9% and a 
specificity of 70.6 and 41.2% % for detection of bone metas-
tases with NaF PET/CT and BS, respectively. The overall 
accuracy was 90% for 18F-fluoride PET/CT and 78% for BS 
[12]. Poulsen et al. compared NaF PET/CT with BS in 50 
patients for detection of spine metastases in 50 patients [15]. 
On a lesions basis (526 lesions included) they found a sensi-
tivity and specificity of 51 and 82% for BS and 93 and 54% 
for NaF PET/CT, respectively. The low specificity of NaF 
PET/CT was attributed to the high number of false-positive 
lesions due to degenerative and inflammatory lesions. The 
low specificity found by the group of Poulsen is in contrast 
to the found high specificities found in other studies. As 
showed by our data the combination of NaF PET with CT is 
able to accurately differentiate benign from malignant NaF 
uptake, since benign uptake is commonly found in joints, 
between vertebral bodies and at sites of tendon insertions in 
contrast to bone metastases, which are normally found inside 
bones, at sites in the skeleton were bone marrow is present. 
Also findings on CT contribute to differentiation. Degenera-
tive findings such as osteophytes and joint narrowing and 
calcifications in muscle tendons relate increased NaF uptake 
to benign processes with high accuracy.
In our cohort low-dose CT showed lymphadenopathy 
in the pelvis in 50% of patients. In 25% of these patients 
evidence of lymph node metastases was found without evi-
dence of other metastases and in most cases this resulted 
in changes in clinical management. This shows that NaF 
PET/CT has, in addition to better detection of bone metas-
tases, additional clinical value over BS in terms of detection 
of lymph node metastases. When detection of soft tissue 
metastases becomes more important in the primary staging 
of prostate cancer, given the options to treat oligo metastatic 
disease, PET/CT with other tracers, for example 68Ga- or 
18F-PSMA, would probably be more suited than NaF PET/
CT. However, evidence is needed that PSMA PET/CT is able 
to diagnose bone metastases with at least the same accuracy 
as NaF PET/CT.
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In literature high specificity of a contrast enhanced CT 
for detection of lymph node metastases is reported, while 
the sensitivity is generally poor [21–24]. For detection of 
enlarged lymph nodes the use of a low-dose CT without 
intravenous contrast agents is insufficient and pathological 
lymph nodes may have been missed in our cohort, which is 
a drawback of the presented data. The recently published 
European Guidelines on prostate cancer instructs to perform 
at least cross-sectional abdominopelvic imaging (MRI or 
CT) and BS for intermediate-risk and high-risk prostate can-
cer. This would support the use of a diagnostic CT with an 
intravenous contrast agent [9]. Thereby NaF PET/CT can be 
used as a modality for both bone scan and cross-sectional 
abdominopelvic imaging, except for those patients for which 
MRI is indicated to stage the primary tumour.
A limitation of this study is the inability to compare with 
specific numbers how NaF PET/CT placed patients into dif-
ferent treatment strategies as compared to BS, which is a 
result of the character of the study. The comparison of two 
different cohorts prevents specification of the additional 
value that one scan has above another on the initated treat-
ment in all patients.
Concerning costs, a general comparison of the expenses 
involved with BS and NaF PET/CT is hard to make. These 
costs are highly dependent on the facilities within a medical 
center or in the local area. PET scans tend to be more expen-
sive than conventional scintigraphic procedures. However 
a tendency is seen in which PET scans and especially PET 
radiopharmaceuticals become less expensive due to several 
factors, including decreased required doses of radiophar-
maceuticals and decreasing costs of PET radiopharmaceuti-
cals. On the other hand, investments needed for replacement 
of aged existing reactors needed for production of 99mTc 
containing radiopharmaceuticals, may result in increased 
expenses involved with conventional BS. As a result the use 
of PET/CT imaging for bone metastases may become worth-
while, especially when the benefits for the patient, including 
better placement of patients into treatment strategies are also 
taken into account.
This study is limited in the ability to compare, with spe-
cific numbers, how NaF PET/CT placed patients into dif-
ferent treatment strategies as compared to BS, which is a 
result of the character of the study. The comparison of two 
different cohorts prevents specification of the additional 
value that one scan has above another on the initiated treat-
ment in all patients. Therefore it would be of great interest to 
prospectively study the impact of BS and NaF PET/CT in a 
single cohort, taken into account effects on patient treatment 
strategies and cost-effectiveness.
Concerning radiation safety of employees, there are no 
significant differences between the use of 18F-FDG and NaF. 
Therefore the use of NaF will fall within common practice of 
a well running PET department. Concerning radiation safety 
of patients the use of NaF PET/CT instead of BS will result 
in higher effective doses, which will be around 3.1 mSv for 
550 MBq of 99mTc-HDP and 4.5 mSv for 189 MBq of NaF 
[25]. Additional imaging for bone metastases is indicated 
in patients with high risk prostate cancer, which are most 
frequently treated with radiation therapy in case of local-
ized or oligo metastasized disease or, in case of metastasized 
disease, with systemic treatment strategies, which at present 
often include docetaxel early in the course of the disease. 
Taken into account the side effects of those treatment strat-
egies, the additional radiation dose of NaF PET/CT is not 
clinically significant.
Conclusion
The present study shows a better diagnostic performance 
for NaF PET/CT as compared to BS for detection of bone 
metastases in primary staging of prostate cancer patients. 
Less equivocal findings are encountered with NaF PET/
CT. Further diagnostic procedures were needed in only 
2% of patients in the NaF cohort compared to 16% in the 
BS cohort. In addition NaF PET/CT detected lymph node 
metastases in half of the included patients, which resulted in 
alterations in clinical management in 25% of those patients.
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